Blood tests may reveal hidden eye damage in diabetes
NCT ID NCT07434362
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study measured three substances in the blood (endocan, alarin, and galanin-like peptide) in people with and without diabetic retinopathy, an eye complication of diabetes. Researchers compared these levels across different stages of the disease and looked at how they relate to eye scan images. The goal was to see if these markers could help identify or track the severity of diabetic retinopathy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fethi Sekin City Hospital
Elâzığ, Elaziğ, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- FitBit coaching may help amputees walk more after surgery
- AI eye doctor: could software catch diabetic blindness sooner?
- Can AI catch the leading cause of blindness before It's too late?
- Does feeling stigmatized worsen life quality for men with low testosterone?
- Can community hospitals in zambia master severe disease care?
- Can a wearable sensor beat Finger-Prick tests for type 2 diabetes?